Ogm

Bionano’s Optical Genome Mapping for Acute Lymphoblastic Leukemia Subjects at the University Hospitals Leuven, Belgium, Has Faster Turnaround Time, Higher Success Rates and Lower Cost per Sample Compared to Traditional Methods

Retrieved on: 
Monday, July 19, 2021
Laboratory techniques, Pediatric cancers, Leukemia, Ogm, Acute lymphoblastic leukemia, Assay, Branches of biology, Medical specialties, Academic disciplines

An assay was developed for whole genome analysis of acute lymphoblastic leukemia (ALL) subjects which, relative to traditional methods, resulted in a workflow with significantly faster turnaround time, higher success rates, and lower cost per sample.

Key Points: 
  • An assay was developed for whole genome analysis of acute lymphoblastic leukemia (ALL) subjects which, relative to traditional methods, resulted in a workflow with significantly faster turnaround time, higher success rates, and lower cost per sample.
  • OGM showed 100% concordance with the traditional methods with no false positives.
  • Dr. Dewaele summarized that their hospital plans to develop more OGM-based assays for other types of leukemias.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Bionano’s Optical Genome Mapping Reveals New Insights and Prognostic Capabilities Compared to Traditional Cytogenetics Techniques in Several Leukemia Clinical Research Studies Presented at the ECA

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Biology, Cytogenetics, Molecular biology, Laboratory techniques, Anatomical pathology, Fluorescence in situ hybridization, Pathology, Karyotype, Ogm, Polymerase chain reaction, Genome

SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented at the 2021 European Cytogenomics Conference (ECA).

Key Points: 
  • SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented at the 2021 European Cytogenomics Conference (ECA).
  • In this study, 34 pediatric leukemias (26 ALL and 8 AML) were analyzed by OGM relative to traditional cytogenetics techniques (karyotyping, FISH, and PCR).
  • This study is the basis of validation and accreditation of an assay to be used onsite in their lab.
  • In 45% of cases, OGM provided additional information, orthogonally confirmed, demonstrating an improvement in diagnostic potential relative to traditional cytogenetics techniques.

Bionano Genomics Announces Back-to-Back Publications in the American Journal of Human Genetics that Compare Optical Genome Mapping to Traditional Methods for Structural Variant Analysis in Inherited Genetic Disease and Hematological Malignancies

Retrieved on: 
Wednesday, July 7, 2021
Genetic analysis, Genetics, Ogm

I think it could be the most significant technological breakthrough in the history of cytogenetics since the CNV-microarray.

Key Points: 
  • I think it could be the most significant technological breakthrough in the history of cytogenetics since the CNV-microarray.
  • Our goals are to provide workflows that find more variants, faster, so critically important information is available sooner and more reliably.
  • Erik Holmlin, PhD, chief executive officer of Bionano Genomics, commented Bionano is poised to substantially transform genetic analysis with OGM and these publications set the baseline for the transformation.
  • We believe OGM with our Saphyr system has the potential to similarly redefine structural variant analysis in genetics and cancer.

Bionano Chief Medical Officer Presents Vision for Optical Genome Mapping as a First Line Clinical Tool for Cancer and Genetic Disease Testing at Festival of Genomics & Biodata

Retrieved on: 
Wednesday, January 27, 2021
Genetic disorder, Ogm, Genomics

As a first line test, OGM would be the first test applied to diagnose the patient and to determine their prognosis and management strategy.

Key Points: 
  • As a first line test, OGM would be the first test applied to diagnose the patient and to determine their prognosis and management strategy.
  • The Festival of Genomics & Biodata is a global virtual event with more than 5,000 attendees, taking place January 26-29, 2021.
  • On day one of the event, Dr. Chaubey presented a large number of genetic disease and cancer cases where patient samples were analyzed with OGM and disease-causing structural variants were identified.
  • Todays presentation at the Festival of Genomics & Biodata supported that belief with an overwhelming amount of evidence generated by Bionano users around the world.